Frontiers in CardioVascular Biomedicine (FCVB) 2022 Budapest is on in person! The excellent programme proves that scientists won against COVID-19

Cardiovasc Res. 2022 Jun 29;118(8):e59-e61. doi: 10.1093/cvr/cvac064.

Péter Ferdinandy^{1

2}, Ákos Koller^{3

4

5

6}, Christian Weber^{7

8

9

10}, Johann Wojta^{11

12}, Johannes Waltenberger^{13

14

15}

¹ Cardiometabolic Research Group and MTA-SE System Pharmacology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Üllői út 26, Budapest 1085, Hungary.
² Pharmahungary Group, Szeged, Hungary.
³ Department of Morphology and Physiology, Faculty of Health Sciences, Budapest 1085, Hungary.
⁴ Department of Translational Medicine, Faculty of Medicine, Semmelweis University, Üllői út 26, Budapest 1085, Hungary.
⁵ Res Center for Sports Physiology, Hungarian University of Sports Science, Budapest 1085, Hungary.
⁶ New York Medical College, Valhalla, NY, USA.
⁷ Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximillians-Universität (LMU) München, Munich, Germany.
⁸ German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany.
⁹ Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
¹⁰ Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands.
¹¹ Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria.
¹² Ludwig Boltzmann Institute for Cardiovascular Research, Vienna, Austria.
¹³ Chair of Cardiology and Vascular Medicine, Medical Faculty, University of Münster, Münster, Germany.
¹⁴ Diagnostic and Therapeutic Heart Center, Kappelistr. 35, 8002 Zürich, Switzerland.
¹⁵ Hirslanden Klinik im Park, Seestrasse 220, 8002 Zürich, Switzerland.

No abstract available

MeSH terms